Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D. Devarakonda S, et al. Among authors: ward jp. Clin Cancer Res. 2019 Oct 15;25(20):6119-6126. doi: 10.1158/1078-0432.CCR-19-0879. Epub 2019 Jul 12. Clin Cancer Res. 2019. PMID: 31300452 Free PMC article.
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
Devarakonda S, Li Y, Martins Rodrigues F, Sankararaman S, Kadara H, Goparaju C, Lanc I, Pepin K, Waqar SN, Morgensztern D, Ward J, Masood A, Fulton R, Fulton L, Gillette MA, Satpathy S, Carr SA, Wistuba I, Pass H, Wilson RK, Ding L, Govindan R. Devarakonda S, et al. J Clin Oncol. 2021 Nov 20;39(33):3747-3758. doi: 10.1200/JCO.21.01691. Epub 2021 Sep 30. J Clin Oncol. 2021. PMID: 34591593 Free PMC article.
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Knapp B, Mezquita L, Devarakonda S, Aldea M, Waqar SN, Pepin K, Ward JP, Botticella A, Howarth K, Knape C, Morris C, Govindan R, Besse B, Morgensztern D. Knapp B, et al. Among authors: ward jp. Front Oncol. 2022 Mar 28;12:856132. doi: 10.3389/fonc.2022.856132. eCollection 2022. Front Oncol. 2022. PMID: 35419282 Free PMC article.
Trends in Stage I Lung Cancer.
Singareddy A, Flanagan ME, Samson PP, Waqar SN, Devarakonda S, Ward JP, Herzog BH, Rohatgi A, Robinson CG, Gao F, Govindan R, Puri V, Morgensztern D. Singareddy A, et al. Among authors: ward jp. Clin Lung Cancer. 2023 Mar;24(2):114-119. doi: 10.1016/j.cllc.2022.11.005. Epub 2022 Nov 21. Clin Lung Cancer. 2023. PMID: 36504141
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL. Ward JP, et al. Blood. 2022 Mar 31;139(13):1999-2010. doi: 10.1182/blood.2021011894. Blood. 2022. PMID: 34780623 Free PMC article. Clinical Trial.
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy.
Salmon AJ, Shavkunov AS, Miao Q, Jarjour NN, Keshari S, Esaulova E, Williams CD, Ward JP, Highsmith AM, Pineda JE, Taneja R, Chen K, Edelson BT, Gubin MM. Salmon AJ, et al. Among authors: ward jp. Cancer Immunol Res. 2022 May 3;10(5):597-611. doi: 10.1158/2326-6066.CIR-21-0129. Cancer Immunol Res. 2022. PMID: 35181783 Free PMC article.
265 results